All scientific staff – University of Copenhagen

Home > Staff > Scientific

Mads Hald Andersen

Mads Hald Andersen

Clinical Professor


  1. 2018
  2. Published

    The inhibitory checkpoint, PD-L2, is a target for effector T cells : Novel possibilities for immune therapy. / Ahmad, Shamaila Munir; Martinenaite, Evelina; Holmström, Morten; Jørgensen, Mia Aaboe; Met, Özcan; Nastasi, Claudia; Klausen, Uffe; Donia, Marco; Pedersen, Lars Møller; Munksgaard, Lars; Ødum, Niels; Woetmann, Anders; Svane, Inge Marie; Andersen, Mads Hald.

    In: OncoImmunology, Vol. 7, No. 2, e1390641, 2018.

    Research output: Contribution to journalJournal article

  3. Published

    The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. / Holmstrom, M. O.; Martinenaite, E.; Ahmad, S. M.; Met, O.; Friese, C.; Kjaer, L.; Riley, C. H.; Straten, P. thor; Svane, I. M.; Hasselbalch, H. C.; Andersen, M. H.

    In: Leukemia, Vol. 32, No. 2, 2018, p. 429-437.

    Research output: Contribution to journalJournal article

  4. Accepted/In press

    Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. / Holmström, Morten Orebo; Riley, Caroline Hasselbalch; Skov, Vibe; Svane, Inge Marie; Hasselbalch, Hans Carl; Andersen, Mads Hald.

    In: OncoImmunology, 2018.

    Research output: Contribution to journalJournal article

  5. Published

    Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. / Kjaer, Lasse; Holmström, Morten O; Cordua, Sabrina; Andersen, Mads Hald; Svane, Inge Marie; Thomassen, Mads; Kruse, Torben A; Pallisgaard, Niels; Skov, Vibe; Hasselbalch, Hans C.

    In: Leukemia and Lymphoma, Vol. 59, No. 4, 04.2018, p. 973-977.

    Research output: Contribution to journalJournal article

  6. Published

    Frequent adaptive immune responses against arginase-1. / Martinenaite, Evelina; Mortensen, Rasmus Erik Johansson; Hansen, Morten; Orebo Holmström, Morten; Munir Ahmad, Shamaila; Grønne Dahlager Jørgensen, Nicolai; Met, Özcan; Donia, Marco; Svane, Inge Marie; Andersen, Mads Hald.

    In: OncoImmunology, Vol. 7, No. 3, e1404215, 2018.

    Research output: Contribution to journalJournal article

  7. Published

    The choriocarcinoma cell line JEG-3 upregulates regulatory T cell phenotypes and modulates pro-inflammatory cytokines through HLA-G. / Melsted, Wenna Nascimento; Matzen, Sara Hyldig; Andersen, Mads Hald; Hviid, Thomas Vauvert F.

    In: Cellular Immunology, 02.2018.

    Research output: Contribution to journalJournal article

  8. 2017
  9. Published

    Anti-regulatory T cells. / Andersen, Mads Hald.

    In: Seminars in Immunopathology, Vol. 39, No. 3, 2017, p. 317–326.

    Research output: Contribution to journalReview

  10. Published

    Cancer and autoimmunity. / Andersen, Mads Hald.

    In: Seminars in Immunopathology, Vol. 39, No. 3, 04.2017, p. 241-243.

    Research output: Contribution to journalEditorial

  11. Published

    Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. / Donia, Marco; Harbst, Katja; van Buuren, Marit; Kvistborg, Pia; Lindberg, Mattias F; Andersen, Rikke; Idorn, Manja; Munir Ahmad, Shamaila; Ellebæk, Eva; Mueller, Anja; Fagone, Paolo; Nicoletti, Ferdinando; Libra, Massimo; Lauss, Martin; Hadrup, Sine Reker; Schmidt, Henrik; Andersen, Mads Hald; Thor Straten, Per; Nilsson, Jonas A; Schumacher, Ton N; Seliger, Barbara; Jönsson, Göran; Svane, Inge Marie.

    In: Cancer research, Vol. 77, No. 17, 01.09.2017, p. 4562-4566.

    Research output: Contribution to journalJournal article

  12. Published

    The role of dendritic cells in cancer. / Hansen, Morten; Andersen, Mads Hald.

    In: Seminars in Immunopathology, Vol. 39, No. 3, 2017, p. 307-316.

    Research output: Contribution to journalReview

Previous 1 2 3 4 5 6 7 8 9 Next

ID: 13571778